Keros Therapeutics (KROS) Receivables - Net (2021 - 2025)

Keros Therapeutics' Receivables - Net history runs 4 years deep, the most recent figure standing at $3.6 million for Q4 2025.

• Quarterly Receivables - Net rose 30.09% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 30.09% YoY) and the FY2025 annual result came in at $3.6 million, up 30.09% from the prior year.
• Receivables - Net was $3.6 million for Q4 2025 at Keros Therapeutics, up from $3.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $18.0 million in Q4 2021 and bottomed at $4000.0 in Q2 2024.
• A 4-year average of $5.6 million and a median of $2.7 million in 2024 frame the typical range for Receivables - Net.
• Peak annual rise in Receivables - Net reached 395300.0% in 2025, while the deepest fall reached 30.09% in 2025.
• Keros Therapeutics' Receivables - Net stood at $18.0 million in 2021, then plunged by 99.21% to $143000.0 in 2023, then soared by 1817.48% to $2.7 million in 2024, then surged by 30.09% to $3.6 million in 2025.
• Business Quant data shows KROS's Receivables - Net at $3.6 million in Q4 2025, $3.5 million in Q3 2025, and $15.8 million in Q2 2025.